Stay updated with breaking news from Recommended Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CLN-081 continues to demonstrate a differentiated clinical profile at the recommended Phase 2 dose of 100mg BID Continued high response rate with favorable safety and tolerability profile observed in... | December 16, 2021
Press release content from PR Newswire. The AP news staff was not involved in its creation.
BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in China LUND, SE / ACCESSWIRE / December 10, 2021 / BioInvent International AB , a biotech company... | December 10, 2021
LUND, SE / ACCESSWIRE / December 10, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory
/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...